anadelumab for treatment of COVID-19 disease

Completed

• Conditions: corona virus; COVID-19; 10047438

• Registration Number: NL-OMON55152
• Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2021-02-25
• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 43

Inclusion Criteria

1. Patient is SARS-COV2 positive (PCR)
2. Without oxygen a saturation below 90% and or at least 3L/min oxygen dependent
3. Patient is 16 years and older

Exclusion Criteria

1. Has previously participated in this study
2. Acute myocardial or cerebral ischemic event at time of enrolment
3. Receiving an agent that is specified as an intervention in this domain as a
usual medication prior to this hospitalization will exclude a patient from
receiving that agent
4. A baseline alanine aminotransferase or an aspartate aminotransferase that is
more than five times the upper limit of normal will result in exclusion from
receiving lanadelumab
5. Patient is known hypersensitive to full human monoclonal antibodies.
6. Patient is pregnant or breast feeding

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Oxygen use patients on lanadelumab versus standard of care and historical<br /><br>controls</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Adverse events patients on lanadelumab versus standard of care and historical<br /><br>controls</p><br>